Another side effect of NSAIDs

Article Abstract:

Nonsteroidal anti-inflammatory drugs (NSAIDs) are becoming increasingly popular for their pain-relieving, fever-reducing, and anti-inflammatory effects. However, these agents are associated with side effects, including hepatotoxicity (toxic effects on the liver). A report of one fatality due to fulminant (massive) hepatitis among seven patients who took diclofenac (Voltaren), an NSAID, is presented in the November 28, 1990 issue of The Journal of the American Medical Association. Reports from Europe, where the drug has been used for some time, include three fatalities from fulminant hepatitis in people who used the drug. Two related drugs have been removed from the market in Europe because of hepatitis-associated fatalities or elevations of liver enzyme concentrations. Patients who seem most vulnerable to this complication are women older than 50 who are under treatment for a rheumatic or arthritic condition, and who are taking other NSAIDs. Patients' medical histories with respect to drug or alcohol abuse, other diseases, foreign travel, and other factors may also play a role in whether a drug reaction takes place. How diclofenac and other NSAIDs lead to hepatotoxicity is not known. Hypotheses regarding this are briefly discussed. Until the level of knowledge about side effects is improved, the liver function of patients who use NSAIDs should be monitored. These drugs should be used cautiously for non-serious complaints. (Consumer Summary produced by Reliance Medical Information, Inc.)

Causes of, Liver, Dosage and administration, Diclofenac, Hepatitis, editorial

---

Adverse Upper Gastrointestinal Effects of Rofecoxib Compared With NSAIDs

Article Abstract:

Rofecoxib appears to have fewer gastrointestinal (GI) side effects than other non-steroidal anti-inflammatory drugs (NSAIDs). Rofecoxib inhibits an enzyme called cyclooxygenase 2 (CO-2). Researchers reviewed 8 randomized clinical trials covering 5,435 patients with osteoarthritis that compared rofecoxib to other NSAIDs. Those who took rofecoxib were half as likely to develop gastrointestinal side effects such as upper GI tract perforations, gastroduodenal ulcers and upper GI tract bleeding (PUBs).

Drug therapy, Osteoarthritis, Rofecoxib

---

COX-2--Selective NSAIDs: New and Improved?

Article Abstract:

Celecoxib may cause fewer gastrointestinal side effects than other non-steroidal anti-inflammatory drugs (NSAIDs). This drug belongs to a class of drugs called COX-2 inhibitors. A study published in 2000 showed it was more tolerable than other NSAIDs, but the study only lasted six months.

Editorial, Celecoxib

Similar abstracts:

• Abstracts: Twins and triplets: The effect of plurality and growth on neonatal outcome compared with singleton infants. Appendicitis in pregnancy: new information that contradicts long-held clinical beliefs
• Abstracts: Assessing the long-term effect of a surface penetrating sealant. Porcelain esthetics for the 21st century
• Abstracts: The clinical course of osteoporosis in anorexia nervosa: a longitudinal study of cortical bone mass
• Abstracts: Delivery of dehydroepiandrosterone to premenopausal women: effects of micronization and nonoral administration
• Abstracts: Intrauterine growth retardation and preterm delivery. Effects of fetal sex and race on risk of very preterm birth in twins

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.